---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-026724"
form_type: "8-K"
ticker: "OGEN"
cik: "0001174940"
company_name: "ORAGENICS INC"
filed_at: "2024-07-10T23:59:59+00:00"
generated_at: "2026-05-31T21:58:48.108119+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Oragenics develops improved intranasal formulation for concussion drug ONP-002

## Summary
- New formulation of ONP-002 designed to enhance brain uptake via nasal cavity, potentially reducing concussion symptoms.
- Oragenics reports increased final dose levels and improved intranasal adhesion for longer absorption times.
- Phase II study in concussed patients being planned to assess safety, feasibility, and effectiveness using blood biomarkers.
- Concussion is a serious unmet need with 69 million cases annually worldwide; leads to long-term disability in up to 20%.

## SEC filing metadata
- accession: 0001493152-24-026724
- form_type: 8-K
- ticker: OGEN
- cik: 0001174940
- company_name: ORAGENICS INC
- filed_at: 2024-07-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1174940/000149315224026724/0001493152-24-026724-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1174940/000149315224026724/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-026724
- JSON: https://secwatch.observer/filing/0001493152-24-026724.json
- Plain text: https://secwatch.observer/filing/0001493152-24-026724.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.